Our Shareholders

Since 13 March 2014, UCB’s capital amounts to € 583 516 974, divided in 194 505 658 ordinary shares with no nominal value.

The main shareholder of UCB is Financière de Tubize SA, a Belgian company listed on Euronext Brussels. The latest shareholding structure of Financière de Tubize SA is available here. 

Shareholder Structure

Source

Latest notifications and shareholder identification (as of January 2026), UCB underlying ownership analysis

close

62% Free Float

Institutional investors:
Geographic distribution

Shareholders' Meetings

The Ordinary General Meeting of Shareholders is held on the last Thursday of April at 11:00 CET.

Shareholders' Meeting Archives



Consensus

Estimates are derived from the Visible Alpha consensus1 dated 16 November 2026. Consensus figures reflect contributions from 13 broker models2.

UCB FY Consensus Earnings Estimates (Average) 
In € million

2025a 

2026e

2027e

2028e

2029e

2030e

2031e

Net Sales

7,388

8,375

9,479

10,629

11,710

12,651

13,297

Revenue

7,741

9,076

10,107

11,222

12,250

13,156

13,619

Research and Development expenses

1,822

2,047

2,271

2,421

2,572

2,675

2,645

Marketing & Selling expenses

2,485

2,665

2,884

3,094

3,214

3,320

3,379

General and administrative expenses

264

290

309

328

343

356

369

Other operating (income)/expenses

-829

-823

-948

-1,037

-1,116

-1,196

-1,188

Adjusted EBIT

2,009

2,768

3,192

3,781

4,403

4,989

5,433

Adjusted EBITDA

2,636

3,427

3,945

4,559

5,234

5,866

6,250

Adj. EBITDA ratio

34.1%

37.8%

39.0%

40.6%

42.7%

44.6%

45.9%

Net Profit

1,558

2,205

2,566

3,063

3,633

4,170

4,515

Core EPS (€)

9.99

13.29

15.30

18.02

21.18

24.13

26.25

 

Consensus on asset lines below includes 11 contributions from broker models via Visible Alpha

 
UCB FY Consensus Product Sales Estimates (Average) 
In € million

2025a 

2026e

2027e

2028e

2029e

2030e

2031e

Product Portfolio       
Cimzia

1,954

1,9611,8681,6961,5161,3751,206
Bimzelx

2,227

3,2654,3735,4646,4537,2127,732
Evenity*

137

180218252274291287
Rystiggo

332

412520615693760816
Zilbrysq

217

308414502579636705
Vimpat

303

220191162147135120
Keppra

439

427382349318294276
Briviact

758

516328258217194187
Fintepla

427

500607689755801795
Nayzilam

128

166177174149130122
Kygevvi 204689130173212
Potential New Products non-risk adjusted
Dapirolizumab pegol

 

  78176283429
Staccato alprazolam

 

 3358102143151
Bepranemab

 

  55156217363

*European sales, ex-EU sales booked by Amgen/Astellas

 

  • 1Disclaimer

    The information provided by Visible Alpha cited herein provided “as is” and “as available” without warranty of any kind. Use of any Visible Alpha data is at your own risk and Visible Alpha disclaims any liability for use of the Visible Alpha data.
    Although the information is obtained or compiled from reliable sources Visible Alpha neither can nor does guarantee or make any representation or warranty, either express or implied, as to the accuracy, validity, sequence, timeliness, completeness or continued availability of any information or data, including third-party content, made available herein.
    In no event shall Visible Alpha be liable for any decision made or action or inaction taken in reliance on any information or data, including third-party content. Visible Alpha further explicitly disclaims, to the fullest extent permitted by applicable law, any warranty of any kind, whether express or implied, including warranties of merchantability, fitness for a particular purpose and non-infringement.

  • 2Contributing brokers
    BrokerModel date
    AlphaValue

    26-Oct-2026

    Berenberg

    05-Nov-2026

    BofA

    26-Oct-2026

    Cowen

    23-Oct-2026

    Deutsche Bank

    23-Oct-2026

    Goldman Sachs

    13-Nov-2026

    Jefferies

    22-Oct-2026

    Morgan Stanley

    24-Aug-2026

    Redburn

    10-Nov-2026

    UBS

    31-Jul-2026

    ODDO

    05-Aug-2026

    ING

    10-Aug-2026

    Intron Health

    22-Oct-2026

     


Dividends

The Board intends to continue to sustain a dynamic dividend policy, consistent with the long-term growth prospects of the Company, offering gradual increase in dividend, and as far as possible not to reduce it, irrespective of the short-term income variations.

The Board of Directors proposes to pay a gross dividend of € 1.45 per share (gross), to be approved by the 2026 annual general meeting of the shareholders.

  • Coupon # 29
  • Ex-dividend: 4 May 2026
  • Record date: 5 May 2026
  • Payment: 6 May 2026

Coupon # 29 of UCB shares is payable at € 1.015 net per share after deduction of Belgian withholding tax of 30%*, via our paying agent, KBC Bank NV.

* Lower withholding tax rates may be applicable depending on the specific situation of each shareholder.


Investor Relations Team

Please reach us via investor-relations@ucb.com or a specific team member:

Yvonne Naughton

Head of Investor Relations

+44-175-344 7521

Yvonne.Naughton@ucb.com

Sahar Yazdian

Investor Relations Lead Lead

+32 2 559 9137
Sahar.Yazdian@ucb.com

Diyana Mishu

Investor Relations Manager

+32 2 559 7446

Diyana.Mishu@ucb.com

Yifei (Faye) Wu

Assistant Assistant Assistant  

+32 2 559 9087

Yifei.Wu@ucb.com